Cardiovascular safety of non-steroidal anti-inflammatory drugs

Safety of non-steroidal anti-inflammatory drugs.

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in medical practice for treating pain, inflammation and degenerative joint diseases (for instance, arthritis). The use of traditional NSAIDs (tNSAIDs), however, is associated with an increased risk of minor and serious gastrointestinal (GI) events. It is estimated that in the European Union thousands of gastrointestinal complication...

Non-steroidal anti-inflammatory drugs.

Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks

While aspirin may offer protection, other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can cause serious cardiovascular side effects and complications. This has led to a general "black box" warning for cardiovascular adverse events for NSAIDs. This review explores the different mechanisms underlying the protective effects of aspirin, the NSAID associated renovascular effects causi...

Cardiovascular complications of non-steroidal anti-inflammatory drugs.

Coxibs, such as rofecoxib, celecoxib, and valdecoxib, selectively inhibit cyclooxygenase (COX)-2, the mainly inducible, pro-inflammatory COX isoform. Unlike traditional non-steroidal anti-inflammatory drugs (NSAIDs) most coxibs do not significantly inhibit COX-1 and are therefore less toxic to the gastrointestinal tract. Hence, coxibs widely replaced traditional NSAIDs for treatment of arthriti...

Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications

In February 2014, the US Food and Drug Administration (FDA) convened an advisory committee meeting to discuss the accumulated data relating to the cardiovascular risk of non-steroidal anti-inflammatory drugs (NSAIDs) and the potential implications on the class prescription labeling. The committee recommended, though not unanimously, that (1) the current data does not support the conclusion that...